A PROSPECTIVE STUDY OF THE EFFICACY AND ADVERSE EFFECTS OF TOLVAPTAN FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

被引：0
|
作者：
Kai, Hirayasu [2 ]
Tsunoda, Ryoya [2 ]
Kawamura, Tetsuya [2 ]
Fujita, Akiko [2 ]
Kaneko, Shuzo [2 ]
Morito, Naoki [2 ]
Usui, Joichi [2 ]
Saito, Chie [2 ]
Nakamura, Taichi [1 ]
Yamagata, Kunihiro [2 ]
机构：
[1] Mito Kyodo Gen Hosp, Nephrol, Mito, Ibaraki, Japan
[2] Univ Tsukuba, Nephrol, Tsukuba, Ibaraki, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP061
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [2] THE BURDEN OF TOLVAPTAN TREATMENT FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Muto, Satoru
    Kawano, Haruna
    Sugiura, Syou-ichiro
    Kitamura, Kousuke
    Kimura, Masaki
    Isotani, Shuji
    Ide, Hisamitsu
    Yamaguchi, Raizo
    Horie, Shigeo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [3] EFFICACY OF TOLVAPTAN ON AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS IN LATE STAGE CKD
    Hattanda, Fumihiko
    Nishio, Saori
    Takeda, Sayo
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [4] EFFICACY OF TOLVAPTAN ON AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS IN LATE-STAGE CKD
    Hattanda, Fumihiko
    Makita, Minoru
    Takeda, Sayo
    Watanabe, Kanako
    Kawashima, Keisuke
    Kondo, Keiichi
    Ishikawa, Yozou
    Kusunoki, Yoshihiro
    Ishikawa, Yasunobu
    Nishio, Saori
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 106 - 106
  • [5] Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Raina, Rupesh
    Houry, Ahmad
    Rath, Pratik
    Mangat, Guneive
    Pandher, Davinder
    Islam, Muhammad
    Khattab, Ala'a Grace
    Kalout, Joseph K.
    Bagga, Sumedha
    DRUG HEALTHCARE AND PATIENT SAFETY, 2022, 14 : 147 - 159
  • [6] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Jouret, Francois
    Krzesinski, Jean-Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1258 - 1259
  • [7] Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
    Ingelfinger, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1988 - 1989
  • [8] PARAMETERS ASSOCIATED WITH PROGRESSION, PROGNOSIS AND TOLVAPTAN INDICATION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Gkika, Vasiliki
    Louka, Michaela
    Fokas, Stavros
    Tigka, Eirini
    Drakopoulos, Angelos
    Markou, Niki
    Doumani, Georgia
    Kostopoulou, Myrto
    Tsagkatakis, Mihail
    Tsirpanlis, George
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I5 - I5
  • [9] Parameters Associated With Progression, Prognosis, and Tolvaptan Indication in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Gkika, Vasiliki
    Louka, Michaela
    Tigka, Eirini
    Drakopoulos, Angelos
    Kostopoulou, Myrto
    Tsirpanlis, George I.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 155 - 155
  • [10] EVALUATION OF THE EFFECT OF TOLVAPTAN ON OXIDATIVE STRESS IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Rigato, Matteo
    Bertoldi, Giovanni
    Ravarotto, Verdiana
    Carraro, Gianni
    Calo, Lorenzo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
12345